Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report)’s stock price gapped up before the market opened on Monday. The stock had previously closed at $22.51, but opened at $23.56. Chugai Pharmaceutical shares last traded at $23.11, with a volume of 42,987 shares.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on CHGCY shares. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.
Read Our Latest Report on Chugai Pharmaceutical
Chugai Pharmaceutical Price Performance
The company has a market capitalization of $75.26 billion, a PE ratio of 23.82 and a beta of 0.60. The stock’s 50 day simple moving average is $20.87 and its 200-day simple moving average is $24.23.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. The business had revenue of $2.54 billion during the quarter, compared to analyst estimates of $2.29 billion. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. On average, equities analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 earnings per share for the current year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.
See Also
- Five stocks we like better than Chugai Pharmaceutical
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
